AbCellera Biologics' stock surged 5.26% in the after-hours session on Friday, following significant insider purchases reported earlier in the day.

The movement appears to be driven by filings showing acquisitions of common shares by key insiders. Thermopylae Holdings Ltd., a 10% owner of the company, reported acquiring 177,457 common shares. Additionally, Andrew Booth, the Chief Financial Officer of AbCellera Biologics, also reported an acquisition of common shares.

Such purchases by a major shareholder and a senior executive are often viewed by the market as a strong signal of confidence in the company's future prospects, which likely contributed to the positive after-hours price action.